RE:SOME Biogen chatterA hugely consequential decision:' How Biogen's Alzheimer's drug came to face the FDA
By June 7, the regulator will decide on whether to approve aducanumab, a decision that could have far-reaching consequences for patients, Biogen and Alzheimer's research.
Published May 27, 2021
https://www.biopharmadive.com/news/biogen-aducanumab-alzheimers-fda-drug-review/600897/